ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is the lead industry participant in a new £1.5 million grant award from the UK’s innovation agency, Innovate UK, to advance development of its hRPC stem cell therapy candidate for blindness-causing degenerative diseases of the retina.
The grant has been awarded under Innovate UK’s Medicines and Manufacturing Round 1: Challenge Fund and will co-fund a collaborative programme of work to be undertaken by ReNeuron and its partners, the Cell & Gene Therapy Catapult, Roslin Cell Therapies and University College London. The project will allow the generation of further cell banks of ReNeuron’s hRPC cell therapy candidate as well as the development of product release assays for late-stage clinical development and subsequent commercialisation of the therapy.